A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
- PMID: 36112849
- PMCID: PMC9844995
- DOI: 10.1177/0272989X221121747
A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
Abstract
In an introductory tutorial, we illustrated building cohort state-transition models (cSTMs) in R, where the state transition probabilities were constant over time. However, in practice, many cSTMs require transitions, rewards, or both to vary over time (time dependent). This tutorial illustrates adding 2 types of time dependence using a previously published cost-effectiveness analysis of multiple strategies as an example. The first is simulation-time dependence, which allows for the transition probabilities to vary as a function of time as measured since the start of the simulation (e.g., varying probability of death as the cohort ages). The second is state-residence time dependence, allowing for history by tracking the time spent in any particular health state using tunnel states. We use these time-dependent cSTMs to conduct cost-effectiveness and probabilistic sensitivity analyses. We also obtain various epidemiological outcomes of interest from the outputs generated from the cSTM, such as survival probability and disease prevalence, often used for model calibration and validation. We present the mathematical notation first, followed by the R code to execute the calculations. The full R code is provided in a public code repository for broader implementation.
Keywords: R software; cohort state-transition models; cost-effectiveness analysis; markov models; time-dependent; tutorial.
Figures







Similar articles
-
An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example.Med Decis Making. 2023 Jan;43(1):3-20. doi: 10.1177/0272989X221103163. Epub 2022 Jun 30. Med Decis Making. 2023. PMID: 35770931 Free PMC article.
-
A Multidimensional Array Representation of State-Transition Model Dynamics.Med Decis Making. 2020 Feb;40(2):242-248. doi: 10.1177/0272989X19893973. Epub 2020 Jan 28. Med Decis Making. 2020. PMID: 31989862 Free PMC article.
-
Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.Med Decis Making. 2017 May;37(4):340-352. doi: 10.1177/0272989X16651869. Epub 2016 Jun 8. Med Decis Making. 2017. PMID: 27281337 Free PMC article.
-
Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model.BJU Int. 2019 Dec;124(6):962-971. doi: 10.1111/bju.14867. Epub 2019 Jul 31. BJU Int. 2019. PMID: 31298775
-
Markov modeling for the neurosurgeon: a review of the literature and an introduction to cost-effectiveness research.Neurosurg Focus. 2018 May;44(5):E20. doi: 10.3171/2018.2.FOCUS17805. Neurosurg Focus. 2018. PMID: 29712528 Review.
Cited by
-
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.Value Health. 2022 Mar;25(3):409-418. doi: 10.1016/j.jval.2021.07.019. Epub 2021 Nov 2. Value Health. 2022. PMID: 35227453 Free PMC article.
-
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling.Pharmacoeconomics. 2024 Jul;42(7):715-719. doi: 10.1007/s40273-024-01364-0. Epub 2024 Mar 18. Pharmacoeconomics. 2024. PMID: 38498106 Free PMC article. No abstract available.
-
Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.BMJ Open. 2024 Aug 22;14(8):e081270. doi: 10.1136/bmjopen-2023-081270. BMJ Open. 2024. PMID: 39179275 Free PMC article.
-
Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.Value Health. 2022 Aug;25(8):1268-1280. doi: 10.1016/j.jval.2022.03.016. Epub 2022 Apr 28. Value Health. 2022. PMID: 35490085 Free PMC article.
-
A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R.Pharmacoecon Open. 2023 Jul;7(4):507-523. doi: 10.1007/s41669-023-00414-1. Epub 2023 Jun 1. Pharmacoecon Open. 2023. PMID: 37261616 Free PMC article.
References
-
- Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology [Internet]. 2019;75(6):910–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283818308534 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources